8,396 IDEXX Laboratories, Inc. $IDXX Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 222,287 shares of the company’s stock after selling 8,396 shares during the period. Russell Investments Group Ltd. owned 0.28% of IDEXX Laboratories worth $116,372,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in IDEXX Laboratories by 4.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock valued at $479,844,000 after buying an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after buying an additional 288,471 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after buying an additional 23,582 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its position in shares of IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after buying an additional 197,808 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several research analyst reports. Jefferies Financial Group reduced their target price on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Morgan Stanley raised their price target on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. UBS Group lifted their price objective on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. Finally, The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective on the stock. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $717.27.

View Our Latest Stock Analysis on IDEXX Laboratories

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Daniel M. Junius sold 1,200 shares of the company’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total value of $844,884.00. Following the transaction, the director directly owned 2,361 shares of the company’s stock, valued at $1,662,309.27. This represents a 33.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Jonathan Mazelsky sold 25,140 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the transaction, the insider owned 83,803 shares in the company, valued at $58,929,431.57. The trade was a 23.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,428 shares of company stock worth $28,567,934 over the last three months. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $704.23 on Monday. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The company has a market capitalization of $55.48 billion, a PE ratio of 47.49 and a beta of 1.55. The firm has a 50 day moving average price of $562.41 and a two-hundred day moving average price of $573.52. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.22 earnings per share. As a group, analysts predict that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Recommended Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.